NCT00419237View on ClinicalTrials.gov

Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

January 13, 2005

Primary Completion Date

April 15, 2005

Study Completion Date

April 15, 2005

Conditions

Asthma

Interventions

DRUG

GW685698X

GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY